tbuckley/cabot-search huggingface dataset:
An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers
Authors: Elisa Dama, Valentina Melocchi, Fabio Dezi, Stefania Pirroni, Rose Mary Carletti, Daniela Brambilla, Giovanni Bertalot, Monica Casiraghi, Patrick Maisonneuve, Massimo Barberis, Giuseppe Viale, Manuela Vecchi, Lorenzo Spaggiari, Fabrizio Bianchi, Pier Paolo Di Fiore
Journal: Clinical Cancer Research (2016)

The National Lung Cancer Screening Trial has confirmed that lung cancer mortality can be reduced if tumors are diagnosed early, that is, at stage I. However, a substantial fraction of stage I lung cancer patients still develop metastatic disease within 5 years from surgery. Prognostic biomarkers are therefore needed to identify patients at risk of an adverse outcome, who might benefit from multimodality treatment.We extensively validated a 10-gene prognostic signature in a cohort of 507 lung adenocarcinoma patients using formalin-fixed paraffin-embedded samples. Furthermore, we performed an integrated analysis of gene expression, methylation, somatic mutations, copy number variations, and proteomic profiles on an independent cohort of 468 patients from The Cancer Genome Atlas (TCGA).Stage I lung cancer patients (N = 351) identified as high-risk by the 10-gene signature displayed a 4-fold increased risk of death [HR = 3.98; 95% confidence interval (CI), 1.73-9.14], with a 3-year overall survival of 84.2% (95% CI, 78.7-89.7) compared with 95.6% (92.4-98.8) in low-risk patients. The analysis of TCGA cohort revealed that the 10-gene signature identifies a subgroup of stage I lung adenocarcinomas displaying distinct molecular characteristics and associated with aggressive behavior and poor outcome.We validated a 10-gene prognostic signature capable of identifying a molecular subtype of stage I lung adenocarcinoma with characteristics remarkably similar to those of advanced lung cancer. We propose that our signature might aid the identification of stage I patients who would benefit from multimodality treatment. Clin Cancer Res; 23(1); 62-72. ©2016 AACR.
Chronic healthcare expenditure in survivors of sepsis in the intensive care unit
Authors: Maria E. Koster-Brouwer, Kirsten van de Groep, Wietze Pasma, Hugo M. Smeets, Arjen J. C. Slooter, Dylan W. de Lange, Diederik van Dijk, Tom van der Poll, Marc J. M. Bonten, Olaf L. Cremer
Journal: Intensive Care Medicine (2016)
Surgical Diagnosis. A Manual for Practitioners of Medicine and Surgery.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Streamlined genetic testing pathway is developed for women with ovarian cancer
Authors: Jacqui Wise
Journal: BMJ (2016)

The Royal Marsden Hospital in London has been trialling a new gene testing pathway for women with ovarian cancer, which makes the process faster and simpler and allows women to receive personalised treatment promptly.

The pilot study, published in the journal Scientific Reports ,1 included 207 women with ovarian cancer who were offered BRCA gene testing at one of their routine cancer clinic appointments instead of referral to a separate genetic testing clinic.

Testing was carried out by a doctor or nurse in a 30 minute …
Safety of reduced antibiotic prescribing for self limiting respiratory tract infections in primary care: cohort study using electronic health records
Authors: Martin C Gulliford, Michael V Moore, Paul Little, Alastair D Hay, Robin Fox, A Toby Prevost, Dorota Juszczyk, Judith Charlton, Mark Ashworth
Journal: BMJ (2016)

Objective To determine whether the incidence of pneumonia, peritonsillar abscess, mastoiditis, empyema, meningitis, intracranial abscess, and Lemierre’s syndrome is higher in general practices that prescribe fewer antibiotics for self limiting respiratory tract infections (RTIs). Design Cohort study. Setting 610 UK general practices from the UK Clinical Practice Research Datalink. Participants Registered patients with 45.5 million person years of follow-up from 2005 to 2014. Exposures Standardised proportion of RTI consultations with antibiotics prescribed for each general practice, and rate of antibiotic prescriptions for RTIs per 1000 registered patients. Main outcome measures Incidence of pneumonia, peritonsillar abscess, mastoiditis, empyema, meningitis, intracranial abscess, and Lemierre’s syndrome, adjusting for age group, sex, region, deprivation fifth, RTI consultation rate, and general practice. Results From 2005 to 2014 the proportion of RTI consultations with antibiotics prescribed decreased from 53.9% to 50.5% in men and from 54.5% to 51.5% in women. From 2005 to 2014, new episodes of meningitis, mastoiditis, and peritonsillar abscess decreased annually by 5.3%, 4.6%, and 1.0%, respectively, whereas new episodes of pneumonia increased by 0.4%. Age and sex standardised incidences for pneumonia and peritonsillar abscess were higher for practices in the lowest fourth of antibiotic prescribing compared with the highest fourth. The adjusted relative risk increases for a 10% reduction in antibiotic prescribing were 12.8% (95% confidence interval 7.8% to 17.5%, P&lt;0.001) for pneumonia and 9.9% (5.6% to 14.0%, P&lt;0.001) for peritonsillar abscess. If a general practice with an average list size of 7000 patients reduces the proportion of RTI consultations with antibiotics prescribed by 10%, then it might observe 1.1 (95% confidence interval 0.6 to 1.5) more cases of pneumonia each year and 0.9 (0.5 to 1.3) more cases of peritonsillar abscess each decade. Mastoiditis, empyema, meningitis, intracranial abscess, and Lemierre’s syndrome were similar in frequency at low prescribing and high prescribing practices. Conclusions General practices that adopt a policy to reduce antibiotic prescribing for RTIs might expect a slight increase in the incidence of treatable pneumonia and peritonsillar abscess. No increase is likely in mastoiditis, empyema, bacterial meningitis, intracranial abscess, or Lemierre’s syndrome. Even a substantial reduction in antibiotic prescribing was predicted to be associated with only a small increase in numbers of cases observed overall, but caution might be required in subgroups at higher risk of pneumonia.
Post-Marketing Surveillance of Bortezomib Treatment for Multiple Myeloma (MM) in Japan: Results of Interim Analysis by the Velcade Japan Proper Use Guideline Committee
Authors: Shinsuke Iida, Harumi Yamamoto Mukai, Kazuma Ohyashiki, Kensei Tobinai, Shin-ichiro Okamoto, Michinori Ogura, Takayuki Ishikawa, Kiyohiko Hatake, Tomomitsu Hotta
Journal: Blood (2008)
Improved Survival in Patients with Refractory Cytopenias (Low Risk Myelodysplastic Syndrome - MDS) Treated with Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants (allo TCD-HSCTs),
Authors: Amy Jhaveri, Esperanza B Papadopoulos, Ann A Jakubowski, Farid Boulad, Nancy A. Kernan, Trudy N Small, Miguel-Angel Perales, Molly Maloy, Carmen Montes-Gaisan, Richard J. O'Reilly, James W Young, H.R. Castro-Malaspina
Journal: Blood (2011)
B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Specific Copy Number Alterations Are Unique For Progressive Pediatric Chronic Myeloid Leukemia (CML): A Large Cohort Study
Authors: Naomi E van der Sligte, Manuela Krumbholz, Agata Pastorczak, Blanca Scheijen, Josephine T. Tauer, Christina Nowasz, Edwin Sonneveld, Truuske H. de Bock, Tiny G. Meeuwsen - de Boer, Simon V. van Reijmersdal, Roland P. Kuiper, Jutta Bradtke, Markus Metzler, Meinolf Suttorp, Evelina S. De Bont, Frank N. van Leeuwen
Journal: Blood (2013)
Performance characteristics of N terminal pro brain natriuretic peptide (NT-proBNP) and BNP assays in the diagnosis of symptomatic and asymptomatic left ventricular systolic dysfunction in primary care
Authors: Hobbs Fdr., R C Davis, A K Roalfe, J E Kenkre, J Trawinski, M K Davies
Journal: Journal of the American College of Cardiology (2001)
Safe endoscopic removal of a swallowed partial denture with a grip-seal plastic bag
Authors: Wataru Sasao, Tomonori Yano, Yoshikazu Hayashi, Hiroyuki Sato, Yoshimasa Miura, Alan Lefor, Hironori Yamamoto
Journal: Endoscopy (2015)

The accidental ingestion of foreign bodies is becoming more frequent in an aging population. Sharp foreign bodies in the upper gastrointestinal tract should be removed as soon as possible to avoid perforation [1]. Various methods of removal have been reported, in which an overtube, a distal attachment, polypectomy snares, baskets, nets, or forceps have been used [2]. However, each of these methods has associated problems. We report a new method for the safe removal of a swallowed partial denture from the stomach.
Diagnosis and Treatment of Myeloproliferative Neoplasms in Germany: First Results from the SAL-MPN Registry
Authors: Andrea Kaifie, Susanne Isfort, Dominik Wolf, Mathias Hanel, Christoph Maintz, Norbert Gattermann, Uwe Platzbecker, Eray Goekkurt, Ina Boeters, Richard Hansen, Fabian Lang, Joachim R. Goethert, Karla Bennemann, Christoph Rollig, Hubert Serve, Wolfgang E Berdel, Gerhard Ehninger, Tim H Bruemmendorf, Steffen Koschmieder
Journal: Blood (2014)
MetGastric: A randomized phase III study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction.
Authors: David Cunningham, Yung-Jue Bang, Josep Tabernero, Manish A. Shah, Florian Lordick, Stephen Paul Hack
Journal: Journal of Clinical Oncology (2013)

TPS4155 Background: Dysregulation of the HGF/MET pathway in patients with gastroesophageal cancer (GEC) is associated with diminished survival and poor prognostic features, such as nodal and organ metastasis, disease stage and tumor invasiveness. Preclinical data suggest that inhibition of the HGF/MET axis may increase the anti-tumor properties of platinum agents by overcoming HGF-mediated resistance mechanisms. Overexpression and inappropriate activation of the MET pathway has been shown to promote peritoneal metastasis in murine models of GEC. Overexpression of HGF or MET has also been linked to metastatic spread to the liver and peritoneum in patients with GEC. Clinical studies suggest that antibody-based inhibitors of the HGF/MET pathway are active in GEC. Onartuzumab, a monovalent monoclonal antibody, specifically binds to the MET receptor preventing HGF binding thereby inhibiting signal transduction. The most commonly reported adverse events associated with onartuzumab are grade 1–3 peripheral edema, hypoalbuminemia and fatigue. Methods: MetGastric is a randomized placebo-controlled, international phase III study in patients with previously untreated metastatic GEC. Only patients with tumors classified as both HER2-negative and MET-positive (by IHC) are eligible. Patients will be randomized (1:1) to receive mFOLFOX6 plus onartuzumab or mFOLFOX6 plus placebo. A maximum of 12 cycles of mFOLFOX6 are permitted. Onartuzumab or placebo will be continued until disease progression. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, overall response rate, safety and correlative biomarker studies. Primary and secondary analyses will include all randomized patients, analyzed according to treatment arm assignment and MET IHC score. Safety will be assessed in all patients who receive at least one dose of study treatment. This study is open for accrual. Clinical trial information: NCT01662869.
Self-Assembled Heterojunction Carbon Nanotubes Synergizing with Photoimmobilized IGF-1 Inhibit Cellular Senescence
Authors: Wu‐Ya Chen, Run‐Cai Yang, Hui‐Min Wang, Li Zhang, Kaikai Hu, Chu‐Hua Li, Rong You, Liang Yin, Yan‐Qing Guan
Journal: Advanced Healthcare Materials (2016)

Synthesis of artificial and functional structures for bone tissue engineering has been well recognized but the associated cell senescence issue remains much less concerned so far. In this work, surface-modified polycaprolactone-polylactic acid scaffolds using self-assembled heterojunction carbon nanotubes (sh-CNTs) combined with insulin-like growth factor-1 are synthesized and a series of structural and biological characterizations are carried out, with particular attention to cell senescence mechanism. It is revealed that the modified scaffolds can up-regulate the expressions of alkaline phosphates and bone morphogenetic proteins while down-regulate the expressions of senescence-related proteins in mesenchymal stem cells, demonstrating the highly preferred anti-senescence functionality of the sh-CNTs modified scaffolds in bone tissue engineering. Furthermore, it is also found that with sh-CNTs, scaffolds can accelerate bone healing with extremely low toxicity in vivo.
Endoscopic Zenker diverticulotomy using the window technique: a technical trick to improve the field of view
Authors: Jérôme Rivory, Ala Almahayawi, Sabine Roman, Laura Calavas, Jean-Christophe Saurin, Thierry Ponchon, Mathieu Pioche
Journal: Endoscopy (2016)

Endoscopic diverticulotomy is a safe, effective, and simple technique to treat patients with symptomatic Zenker's diverticulum [1]. The endoscopic management was demonstrated to be as effective as surgical external diverticulotomy in most cases and can be recommended as the first choice [2]. Diverticuloscope-assisted diverticulotomy has been demonstrated to be safer and more effective than the cap-assisted procedure [3]. The main benefit of the diverticuloscope is to improve exposure of the muscular fibers by stretching them [4].
Extending Corticostriatal Systems
Authors: Ariel Y. Deutch
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
The Impact of Concurrent MYC BCL2 Protein Expression on the Risk of Secondary Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: Kerry J. Savage, Laurie H. Sehn, Diego Villa, Roopesh R. Kansara, Anja Mottok, Daisuke Ennishi, Susana Ben-Neriah, Robert Kridel, Christian Steidl, King L. Tan, Nathalie Johnson, Graham W. Slack, Joseph M. Connors, Pedro Farinha, David W. Scott, Randy D. Gascoyne
Journal: Blood (2014)
Cancer of unknown primary
Authors: T. H. Fong, R. Govindan, D. Morgensztern
Journal: Journal of Clinical Oncology (2008)

22159 Background: Cancer of unknown primary (CUP) is defined as a histologically-confirmed metastatic malignant tumor whose primary site of origin cannot be determined during the diagnostic evaluation. Despite its relatively common occurrence, there is limited information in the literature. We evaluated the Surveillance, Epidemiology, and End Results (SEER) database for incidence and survival to improve the current knowledge of this malignancy. Methods: The SEER database was searched for CUP (site code C80.9) in patients diagnosed between 1973 and 2004. Results were stratified according to decade of diagnosis to facilitate comparisons. Survival rates were compared by histology, and further stratified according to therapy in patients with squamous and adenocarcinoma. Results: We identified 108,898 patients meeting the inclusion criteria. The incidence of CUP as a proportion of all malignancies decreased from 3.04% in the 70s to 2.11% in the current decade, representing the 10th most common diagnosed malignancy in the US. The median age at presentation is currently 73 years and the disease is slightly more common in women (52%). The median overall survival has been 4 months since the 70s, whereas the 1-year disease-specific survival increased from 23.4% in the 70s to 29.3% in the current decade. Patients with squamous cell carcinoma received both surgery and radiation therapy more often than those with adenocarcinoma (30.9% vs 3.5%). Overall, squamous cell carcinoma was associated with the best median survival (34 months), whereas adenocarcinoma had the worst outcomes (4 months). Conclusions: CUP is a common malignancy representing approximately 2% of new cancers in US. Despite improving diagnostic and therapeutic modalities, there has been a slow progress in defining the primary site and improving overall outcomes for these patients. No significant financial relationships to disclose.
Interval training induces clinically meaningful effects in daily activity levels in COPD
Authors: Zafeiris Louvaris, Stavroula Spetsioti, Eleni A. Kortianou, Maroula Vasilopoulou, Ioannis Nasis, Georgios Kaltsakas, Nikolaos G. Koulouris, Ioannis Vogiatzis
Journal: European Respiratory Journal (2016)

Mounting evidence suggests that daily activity levels (DAL) in patients with chronic obstructive pulmonary disease (COPD) are markedly low compared with healthy age-matched individuals and are associated with poorer health status and prognosis [1]. COPD severity negatively impacts on DAL since patients with low DAL experience greater ventilatory, central haemodynamic and peripheral muscle oxygenation constraints during activities of daily living when compared with more physically active counterparts [2, 3]. Although exercise training as part of pulmonary rehabilitation has shown to mitigate the aforementioned physiological constraints [4], there is no evidence of clinically meaningful improvements in DAL following pulmonary rehabilitation [5] as manifested by a mean increase of at least 1000 steps·day−1 [6]. This has been attributed to methodological shortfalls, such as lack of adequately controlled studies, small sample size, short duration of pulmonary rehabilitation programmes, application of activity monitors non-validated for COPD patients [5] and insufficient exercise intensities to induce true physiological training effects. Interval exercise training has been shown to allow application of intense loads to peripheral muscles that induce substantial physiological effects manifested by mitigation of respiratory and central haemodynamic limitations and partial restoration of peripheral muscle dysfunction in patients with diverse COPD severity [7, 8]. In this context, it is reasoned that application of this training modality would allow transfer of the aforementioned physiological benefits into clinically meaningful improvements in DAL [2, 3]. Accordingly, the purpose of this randomised controlled study was to investigate the effect of a 12-week high-intensity interval exercise training programme in DAL in addition to usual care in patients with COPD. 12 weeks of interval training induces clinically meaningful effects in amount and intensity of daily activities in COPD <http://ow.ly/rZXI3002awp>
18F-FDG PET/CT and Melanoma
Authors: Esther Mena, Mehdi Taghipour, Sara Sheikhbahaei, Sahar Mirpour, Jennifer Xiao, Rathan M. Subramaniam
Journal: Clinical Nuclear Medicine (2016)

We aimed to evaluate the added value of performing fourth and subsequent follow-up F-FDG-PET/CT scans to clinical assessment and impact on the patient's management in patients with melanoma.This was a retrospective study of 232 biopsy-proven melanoma patients who underwent F-FDG-PET/CT scans. Of these, 71 patients had 4 or more follow-up F-FDG-PET/CT scans after completion of primary treatment, with a total of 246 fourth or subsequent follow-up PET/CT scans. The added value of each follow-up PET/CT scan to the patient's clinical assessment and treatment management was established. Kaplan-Meier plots with a Mantel-Cox log-rank test were used to establish the patient's overall survival.Of the 246 fourth and subsequent follow-up PET/CT scans, 61% (150/246) were negative for malignancy, and 39.0% (96/246) were positive for recurrence/metastases. FDG-PET/CT was helpful in identifying malignancy in 6.5% of the scans performed without prior clinical suspicion, which ruled out malignancy in 28.5% of the scans obtained with prior clinical signs suggestive of recurrence or for secondary therapy assessment. The PET/CT scan resulted in change of the patient's management in approximately 16.7% (41/246) of the scans. Change in management was significantly greater in patients whose scans were done with prior clinical signs suggestive of malignancy, or for therapy assessment than without prior clinical suspicion (29.3% vs 4.1%; P < 0.0001). Statistically significant difference was seen in the overall survival between patients with at least 1 positive and all negative fourth and subsequent follow-up PET/CT scans at patient level (P = 0.001).The fourth and subsequent F-FDG-PET/CT scans obtained after completion of primary treatment added value to clinical assessment in patients with melanoma. Patients with clinical signs suggestive of recurrence or metastases or being monitored for treatment response are more likely to benefit from the fourth or subsequent FDG PET/CT than those without prior clinical suspicion.
Oxidation of Glucose-C14 by Human Thyroid Tissues
Authors: P F MULVEY, J J KELLEHER, D W SLINGERLAND
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal